As competition heats up, Novo Nordisk’s share price declines
Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.
Low long-term adherence to weight loss drugs
Only 25% of US patients prescribed Wegovy or Ozempic for weight loss continued usage after two years, raising concerns about long-term adherence.